UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-37685 PAVMED INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 47-1214177 (State or Other Jurisdict ...

PAVmed Inc. (NASDAQ:PAVM) Business Update and Preliminary Q4 2020 Conference Call February 22, 2021 8:30 AM ET Company Participants Mike Havrilla – Director-Investor Relations Lishan Aklog – Chairman and Chief Executive Officer Dennis McGrath – President and Chief Financial Officer Stanley Lapidus – Strategic Advisor-Lucid Diagnostics Conference Call Participants Frank Takkinen – Lake Street Capital Markets Anthony Vendetti – Maxim Group Ed Woo – Ascendiant Capital Operator Greetings, and welcome to PAVmed ...

PAVmed, Inc. (NASDAQ:PAVM) Q3 2020 Earnings Conference Call November 17, 2020 4:30 PM ET Company Participants Mike Havrilla – Director-Investor Relations Lishan Aklog – Chairman and Chief Executive Officer Dennis McGrath – President and Chief Financial Officer Conference Call Participants Frank Takkinen – Lake Street Capital Markets Anthony Vendetti – Maxim Group Ed Woo – Ascendiant Capital Operator Greetings, and welcome to the PAVmed, Inc. Business Update Conference Call. [Operator Instructions] As a remi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended SEPTEMBER 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______ to______ Commission File Number: 001-37685 PAVmed Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 47-1214177 (State or Other ...

彩PAVmed THCARE CONFERENCE Corporate Overview LISHAN AKLOG, MD Chairman & CEO September 15, 2020 Nasdaq: PAVM, PAVMZ Disclaimers This presentation contains certain forward-looking statements that involve risks and uncertainties. • Actual results and events may differ significantly from results and events discussed in forward-looking statements. • Factors that might cause or contribute to such differences include, but are not limited to, those discussed in "Risk Factors" in our Annual Report on Form 10-K and ...

PAVmed Inc. (NASDAQ:PAVM) Q2 2020 Earnings Conference Call August 18, 2020 4:30 PM ET Company Participants Mike Havrilla - Director of Investor Relations Lishan Aklog - Chairman and Chief Executive Officer Dennis McGrath - President and Chief Financial Officer Conference Call Participants Anthony Vendetti - Maxim Group Operator Greetings and welcome to the PAVmed Incorporated Business Update Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow ...

Financial Performance - The net loss attributable to PAVmed Inc. for the six months ended June 30, 2020, was $20,194 million, compared to a net loss of $7,261 million for the same period in 2019, reflecting an increase of 177.5%[11] - The net loss per share attributable to PAVmed Inc. common stockholders for the six months ended June 30, 2020, was $(0.46), compared to $(0.27) for the same period in 2019, indicating a decline in performance[11] - For the six months ended June 30, 2020, the net loss before noncontrolling interest was $20,755,000, compared to a net loss of $7,443,000 for the same period in 2019, indicating a significant increase in losses[24] - The company reported no revenue for the three and six months ended June 30, 2020, consistent with the same periods in 2019[11] - The net loss attributable to PAVmed Inc. was $5,578,000, compared to a net loss of $3,594,000 for the same period in 2019[76] Assets and Liabilities - Total assets increased to $8,882 million as of June 30, 2020, up from $7,240 million as of December 31, 2019, representing an increase of 22.7%[9] - Total liabilities rose significantly to $21,687 million as of June 30, 2020, compared to $11,878 million as of December 31, 2019, marking an increase of 82.6%[9] - The accumulated deficit as of June 30, 2020, was $(73,908) million, compared to $(53,715) million as of December 31, 2019, reflecting an increase of 37.5%[9] - As of June 30, 2019, total stockholders' deficit was $1,879,000, reflecting the financial challenges faced by the company[21] Expenses - Research and development expenses for the six months ended June 30, 2020, were $4,702 million, up from $2,856 million in the same period of 2019, indicating a growth of 64.5%[11] - General and administrative expenses for the three months ended June 30, 2020, were $2,881 million, compared to $1,914 million for the same period in 2019, an increase of 50.5%[11] - The company reported cash flows used in operating activities of $9,346,000 for the six months ended June 30, 2020, compared to $6,389,000 for the same period in 2019, reflecting increased operational expenditures[24] Financing Activities - The company raised $6,300,000 from the issuance of Senior Secured Convertible Notes and $3,700,000 from the issuance of Senior Convertible Notes during the six months ended June 30, 2020, indicating reliance on debt financing[24] - The company intends to rely on capital markets for additional equity or debt financing, highlighting potential risks in securing favorable financing terms[29] - The Company received approximately $300 from the PPP Loan under the CARES Act, which matures on April 8, 2022, and bears interest at approximately 1.0% per annum[71] Stock and Equity - The weighted average common shares outstanding increased to 44,781 million for the three months ended June 30, 2020, compared to 27,606 million for the same period in 2019, a rise of 62.1%[11] - The Company’s stockholders approved an increase to the share reservation of the PAVmed Inc. 2014 Equity Plan by an additional 2,000 shares, raising the total from 8,000 to 10,000 shares[50] - The Company granted 1,345 stock options under the PAVmed Inc. 2014 Equity Plan during the six months ended June 30, 2020[46] Product Development - EsoGuard and CarpX are the primary products focused on commercialization, with ongoing development for other products in the pipeline, including EsoGuard IVD and PortIO[27] - The company has received FDA marketing clearance for EsoCheck and CarpX, enhancing its product portfolio and market readiness[30] - The company has a focus on advancing its innovative medical technologies from concept to commercialization, emphasizing capital efficiency and speed to market[26] Future Outlook - The company expects to continue incurring losses for the foreseeable future, with existing liquidity insufficient to fund operations until significant revenues are achieved[29]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended MARCH 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______ to______ Commission File Number: 001-37685 PAVmed Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 47-1214177 (State or Other Juri ...

PAVmed Inc. (NASDAQ:PAVM) Q1 2020 Results Earnings Conference Call May 21, 2020 4:30 PM ET Company Participants Mike Havrilla - Director of IR Lishan Aklog - Chairman and CEO Dennis McGrath - President & Chief Financial Officer Conference Call Participants Anthony Vendetti - Maxim Group Chris Sommers - Hammerstein Operator Greetings. Welcome to the PAVmed Incorporated Business Update Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the form ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-37685 PAVMED INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 47-1214177 (State or Other Jurisdict ...